US Market News
2週前
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart GapJune 16, 2026 9:11 AM
PR Newswire (US) Issued on behalf of Ventripoint Diagnostics Ltd.As the number of people living with congenital heart disease climbs and most patients in poorer regions go without timely care, a Toronto-based AI imaging company is joining a new global alliance built to close that gap.TORONTO, ON, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — Congenital heart disease is the most common birth defect in the world, and the population living with it is growing, not shrinking. According to the World Heart Federation's World Heart Report 2026, congenital heart disease now affects roughly 2% of live births globally, and the number of people living with the condition has climbed to an estimated 16 million worldwide — up from 11.8 million three decades ago. Yet the same report found that more than 90% of children in lower- and middle-income countries lack timely access to congenital heart disease care. It is a paradox at the heart of modern medicine: better treatment is keeping more patients alive and aging into adulthood, even as access to the diagnostics and monitoring they need remains deeply unequal. Companies mentioned: Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTCQB: VPTDF), HeartFlow, Inc. (Nasdaq: HTFL), Butterfly Network, Inc. (NYSE: BFLY), Tempus AI, Inc. (Nasdaq: TEM), iRhythm Technologies, Inc. (Nasdaq: IRTC)Into that gap steps a coordinated industry response — and a company positioning its technology at the center of it. On June 15, 2026, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTCQB: VPTDF), a pioneer in advanced AI-assisted cardiac imaging, announced its support for the newly forming Global Congenital Heart Disease Alliance (GCHDA), an industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies. As part of its initial efforts, the alliance said it would help fund and place four of Ventripoint's VMS+™ cardiac imaging units to directly support the congenital heart disease community and expand access to advanced diagnostic care.Why Congenital Heart Disease Is a Uniquely Hard ProblemCongenital heart disease is not a single condition but a broad family of structural heart defects present from birth, ranging from minor to life-threatening. What makes it uniquely challenging from a diagnostic standpoint is twofold. First, it is a lifelong condition: thanks to decades of surgical and medical advances, the vast majority of children born with congenital heart defects now survive into adulthood, creating a large and growing population that requires structured, individualized follow-up for the rest of their lives. Second, the anatomy is often complex and irregular — hearts that have been surgically reconstructed or that developed abnormally do not conform to the neat geometric assumptions built into many conventional imaging tools, making accurate measurement genuinely difficult.That combination — a lifelong need for precise, repeated monitoring against anatomy that resists easy measurement — is exactly where imaging technology matters most. The European Society of Cardiology's guidelines for adult congenital heart disease identify the condition as a chronic illness requiring lifelong individualized follow-up, and affirm echocardiography as the key modality for longitudinal assessment of heart function. The problem is that the gold standard for the most accurate measurements, cardiac MRI, is expensive, slow, and scarce — especially in the underserved regions where the access gap is widest. The field has long needed a way to get high-accuracy cardiac measurement to the point of care, without an MRI suite.Ventripoint's Approach: MRI-Level Accuracy From a Standard EchoVentripoint's flagship platform, VMS+™, is built squarely around that need. The technology uses artificial intelligence to transform standard 2D echocardiograms — among the most widely available imaging exams in the world — into highly accurate 3D models of all four chambers of the heart, delivering what the company describes as cardiac-MRI-level measurement accuracy at the point of care. For congenital heart patients, whose complex anatomy often defeats traditional imaging, that capability is especially relevant. The platform is powered by Ventripoint's proprietary Knowledge-Based Reconstruction technology, the product of roughly a decade of development, and is designed to run on existing ultrasound systems from any vendor — meaning hospitals and clinics can expand advanced cardiac imaging without buying new scanners.Crucially for a company addressing a global access gap, VMS+™ carries regulatory clearances in the United States, Europe, and Canada, and beyond congenital heart disease it supports applications including pulmonary hypertension and cardiotoxicity monitoring in oncology patients. The technology has been recognized with a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies category, and has been implemented or evaluated at leading institutions including the Peter Munk Cardiac Centre in Toronto and in clinical studies at the Mayo Clinic. "Congenital heart disease affects patients across every stage of life, from infancy through adulthood," said Joe Hostetter, Director of the CHD Program at Ventripoint, framing accurate, accessible imaging as a necessary part of closing the global care gap.What the GCHDA Membership SignalsThe alliance itself is a notable development for a field that has historically been fragmented. The GCHDA describes itself as a hybrid industry association and innovation consortium, bringing together industry partners, clinicians, researchers, regulators, investors, and patient communities to accelerate congenital cardiovascular technologies through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases. "We exist to bring focused attention and determined project execution to the congenital heart disease community," said Julia Friesen, Executive Director of the alliance, noting that its initial efforts include funding and placing four VMS+ units to expand access to advanced diagnostic care.For Ventripoint, the value is twofold: a direct commercial signal in the planned placement of four units, and a strategic position inside a consortium that could shape how congenital cardiovascular technologies are researched, validated, and adopted worldwide. The company plans to participate in the alliance's programming, including its annual summit and innovation showcases. It is the kind of ecosystem play that, if the alliance gains traction, could give a small-cap imaging company outsized visibility among the clinicians and institutions that drive adoption — though, as with any newly forming organization, the alliance's ultimate impact remains to be proven.A Booming Market for Smarter Cardiac ImagingVentripoint is operating in one of the fastest-growing corners of medical technology. The market for artificial intelligence in cardiology has been projected to grow from roughly US$2.78 billion in 2026 to as much as US$14.2 billion or more by the mid-2030s, reflecting compound annual growth rates north of 20%. Echocardiography — the single most widely used cardiac imaging modality in the world — is itself forecast to expand to around US$2.64 billion by 2030, and portable, point-of-care ultrasound is pushing cardiac assessment out of dedicated imaging labs and into clinics and remote settings. The through-line across all of these trends is a demand for technologies that deliver clinical accuracy and economic value at once. Looking at a few of the public companies attacking adjacent parts of this market helps frame both the opportunity and the competitive landscape.HeartFlow, Inc. (Nasdaq: HTFL) is among the clearest public proxies for AI-driven cardiac imaging. The company's technology uses AI to create personalized 3D models of a patient's coronary arteries from standard CT scans to help diagnose and manage coronary artery disease non-invasively. Having gone public in 2025 and built a multibillion-dollar market capitalization, HeartFlow demonstrates the commercial scale that AI-based cardiac imaging can reach — and, like Ventripoint, it is built on the premise of replacing or deferring more invasive or expensive procedures with smarter software-driven imaging.Butterfly Network, Inc. (NYSE: BFLY) maps most directly to Ventripoint's point-of-care thesis. Butterfly makes a handheld, semiconductor-based ultrasound probe paired with AI software, pushing cardiac and other imaging out of the lab and into emergency, primary-care, and remote settings. As a company explicitly focused on democratizing access to ultrasound imaging, Butterfly illustrates the same core idea animating Ventripoint — bringing advanced imaging to wherever the patient is — albeit through hardware rather than vendor-agnostic software.Tempus AI, Inc. (Nasdaq: TEM) represents the scaled, AI-driven diagnostics platform end of the market. While best known for precision oncology, Tempus has expanded into cardiology — including an FDA-authorized ECG algorithm that has drawn CMS reimbursement — and exemplifies how richly investors are valuing AI-enabled diagnostics with reimbursement pathways and large data ecosystems. It is far larger and broader than Ventripoint, but it underscores the market's appetite for AI that turns routine tests into higher-value clinical insight.iRhythm Technologies, Inc. (Nasdaq: IRTC) rounds out the group as an established success story in AI-driven cardiac diagnostics. Its Zio platform pairs wearable ECG monitors with AI analysis to detect arrhythmias, and the company has built a substantial commercial franchise around turning continuous cardiac data into actionable diagnoses. iRhythm shows that a focused, AI-centric cardiac diagnostics company can scale into a major player — a potential template for what a technology like VMS+™ might aspire to in its own niche. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in size, technology, and stage, and Ventripoint is among the smaller, earlier-stage names.The Investment Lens: Promise and CaveatsThe appeal of Ventripoint's positioning is easy to see. It has a regulatory-cleared, vendor-agnostic technology that addresses a real and growing clinical need; recognition from clinicians and awards bodies; implementations at respected cardiac centers; and now a seat inside a global alliance with a concrete near-term order for four units. In a market racing toward AI-enabled, point-of-care cardiac imaging, those are meaningful assets, and the congenital heart disease angle gives the company both a humanitarian narrative and a defensible clinical niche where its accuracy advantage matters most.The caveats are equally important. Ventripoint is a small-cap company in the capital-intensive, slow-moving world of medical technology, where adoption cycles are long, hospital procurement is deliberate, and revenue can take years to scale even for clinically validated products. The GCHDA is newly forming, and the placement of four units — while a positive signal — is modest in absolute terms; the alliance's broader promise is, for now, potential rather than proven. The company competes, directly or indirectly, against far larger and better-funded players, and like most small-cap medtechs it faces ongoing financing needs and the risks that come with them. Investors should weigh the genuine clinical merit and strategic positioning against the realities of commercialization at small scale.Why the Trajectory Still MattersStep back, and the larger picture is compelling regardless of any single company's fortunes. The global population living with congenital heart disease is growing, the need for lifelong monitoring is intensifying, the access gap in much of the world remains vast, and the technology to deliver accurate cardiac measurement at the point of care — without an MRI suite — is maturing rapidly. The formation of a dedicated global alliance to coordinate the field's fragmented efforts is itself a sign that the problem is finally drawing focused, cross-sector attention. Ventripoint has placed itself, and its AI imaging platform, squarely inside that movement.Whether the company can convert clinical validation, awards, and alliance membership into durable commercial scale is the question that will define its future, and the path for any small-cap medtech is rarely smooth. But the direction of the field is unmistakable: toward smarter, cheaper, more accessible cardiac imaging, and toward coordinated global efforts to bring it to the millions of congenital heart disease patients who currently go without. For investors tracking where AI meets the future of cardiac care, Ventripoint's latest move is a small but telling marker of that broader shift.CONTINUED … Learn more about Ventripoint Diagnostics Ltd. at: https://usanewsgroup.com/vpt-landing/SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVESEagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.Explore Eagle Eye free (for now) at https://Eagle-Eye.devCONTACT:Equity Insiderinfo@equity-insider.comSOURCES:[1] Ventripoint Diagnostics Ltd. — "Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance" (TheNewswire, June 15, 2026; primary source for the GCHDA support, four VMS+ units, VMS+™ description, WHF 2026 data, management quotes):
https://www.ventripoint.com/news[2] World Heart Federation — World Heart Report 2026 (CHD ~2% of live births; ~16 million people living with CHD, up from 11.8 million; >90% of children in LMICs lack timely CHD care):
https://world-heart-federation.org/world-heart-report-2026/[3] Investing News Network — "Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts" (AI-in-cardiology market ~US$2.78B 2026 to ~US$14.22B; echocardiography ~US$2.64B by 2030; 2020 ESC ACHD guidelines; peer context):
https://investingnews.com/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts/[4] Ventripoint Diagnostics Ltd. / Providence Health Care Ventures — St. Paul's Hospital VMS+™ validation collaboration (FDA-cleared and Health Canada-licensed; runs on existing ultrasound; Peter Munk and Mayo Clinic implementations):
https://phcventures.ca/phc-ventures-ventripoint-ai-cardiac-imaging/[5] HeartFlow, Inc. — Nasdaq listing and AI coronary imaging overview (peer context: HTFL, BFLY, TEM, IRTC public cardiac-imaging / cardiac-AI names):
https://www.nsf.gov/science-matters/heartflows-ai-powered-medical-technology-debuts-nasdaqDISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content to download multimedia:https://www.prnewswire.com/news-releases/16-million-people-one-underserved-disease-the-ai-imaging-push-to-close-the-congenital-heart-gap-302800970.html Original: 16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
US Market News
1月前
Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial FrontsMay 19, 2026 8:55 AM
PR Newswire (US) Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /PRNewswire/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recurring revenue, and which cannot. The companies winning right now are the ones stacking regulatory clearances, commercial partnerships, and reimbursement-friendly clinical evidence at the same time. Industry forecasts help frame the prize at stake. The artificial intelligence in cardiology market has been projected to grow from approximately US$2.78 billion in 2026 to roughly US$14.22 billion by 2034, representing a compound annual growth rate near 22.6% over the period.[1] Echocardiography alone — the most widely used cardiac imaging modality in the world — is forecast to expand to US$2.64 billion by 2030 as health systems demand cardiac platforms that prove economic value alongside clinical accuracy.[2]Read the full report of Ventripoint here: USA News Group Ventrpoint CoveragePortable ultrasound, valued at roughly US$2.79 billion in 2026, is pushing cardiac assessment beyond the imaging lab and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts.[3]Inside that environment, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF) has spent the first half of 2026 stringing together exactly the kinds of validation events that the new procurement environment rewards.The Toronto-headquartered company applies proprietary Knowledge Based Reconstruction technology to standard 2D echocardiograms and produces volumetric cardiac measurements that the company describes as equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems that already sit in hospitals worldwide, regardless of vendor.A Regulatory Submission Into the World's Largest Cardiac Disease PopulationOn April 28, 2026, Ventripoint announced that its strategic partner Lishman Global Inc. had formally submitted the Company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) — the regulatory body commonly referred to as the Chinese FDA — for approval.[4] The filing is the principal regulatory gating event for VMS+ access to the Chinese cardiology market, and according to the Company, Lishman Global qualified for the NMPA's "green channel" pathway, an expedited review process designed for innovative medical technologies that address significant clinical needs.[4]The scale of the opportunity is difficult to overstate. The Company has cited an estimated 330 million cardiovascular disease patients in China, with cardiovascular disease the leading cause of mortality in the country.[4]Echocardiography is already the most widely used cardiac imaging modality in China because of its cost-effectiveness, portability, and scalability across both urban and rural healthcare settings.[4] What the market has been short on, in Ventripoint's framing, is the kind of AI-driven analytic layer that produces consistent, MRI-equivalent volumetric measurements from those existing ultrasound exams — particularly given variability in image interpretation across operators and limited access to advanced modalities like MRI in many parts of the country."China is one of the most important cardiac care markets in the world," said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics, in the announcement. "With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly."[4] Paul Gibson, Chief Technology Officer of Lishman Global, added that qualification for the NMPA's green channel "underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption."[4]Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageBringing AI Cardiac Imaging Into a Padua-Based European CongressSix days after the NMPA submission was announced, Ventripoint disclosed plans to exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), held May 12–16, 2026 in Padua, Italy.[5] Founded in 1963, AEPC is described as the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries.[5]The 2026 meeting was hosted by the University of Padova and featured a scientific program centred on advanced cardiovascular imaging and artificial intelligence — a fit, the Company argued, for what VMS+ is designed to deliver.[5]A central focus of Ventripoint's booth at AEPC was the use of VMS+ to support evolution of cardiac function over time in congenital heart disease (CHD) patients. The clinical rationale, as the Company described it, sits inside the 2020 ESC Guidelines for Adult Congenital Heart Disease — guidelines co-endorsed by AEPC — which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and which affirm echocardiography as the key modality for longitudinal assessment of ventricular function.[5] The latest release, VMS+ 4.0, was purpose-built around the workflow needs of clinicians, the Company has said, streamlining the time required to generate assessments and making volumetric cardiac analysis accessible at the point of care.[5]"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," MacNaught said in the AEPC announcement. "VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI — giving clinicians the confidence they need to manage their patients at every stage of life."[5]A Wider Pattern of Validation Events Through Spring 2026The NMPA submission and AEPC exhibition are the two most recent links in a chain of events the Company has been building since the start of the year. Earlier in spring 2026, Ventripoint announced its Edison Award recognition, signed a commercial agreement with LG Consulting Solutions to support deployment of VMS+ across Northern California hospital systems, and announced a partnership delivering AI 3D heart mapping into Indigenous community settings through a Nisg_a'a partnership.[6]Considered together, those steps describe a small-cap AI medtech company simultaneously stacking validation across regulatory, commercial, and clinical fronts at the exact moment the broader hospital procurement environment is reorganizing around AI clinical solutions.[6]The LG Consulting Solutions agreement is structured precisely to address the financial proof requirement that has come to dominate hospital adoption decisions. Under the agreement, LG Consulting provides economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology.[6]In other words, the commercial framework on the ground in Northern California is designed to deliver department-level economic justification — which is exactly what hospital procurement is currently demanding before they sign.How Ventripoint Sits Inside a Reshaping Cardiac AI FieldVentripoint is far from the only public company chasing the AI cardiac imaging opportunity. Several larger names have moved aggressively across the past year — and the procurement environment for AI medtech is reshaping in real time as a result.Butterfly Network, Inc. (NYSE: BFLY) is one of the highest-profile names in handheld ultrasound. The Company has continued to expand integrations between its iQ family of probes and third-party AI cardiac applications, including the August 2025 announcement integrating Bordeaux-based DESKi's HeartFocus cardiac examination software into Butterfly's handheld devices — software that received FDA clearance in April 2025 and that allows healthcare professionals with minimal training to capture complete echocardiographic views.[7] Butterfly's strategy of partnering with AI cardiac software vendors places it in a structurally adjacent — but distinct — segment of the cardiac AI market from a knowledge-based reconstruction platform like Ventripoint's VMS+.Tempus AI, Inc. (NASDAQ: TEM) has been one of the cardiology AI sector's most-watched commercial stories. Tempus generated $1.2 billion in revenue for full-year 2025 and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA — projecting its first year of positive adjusted profitability.[1] Tempus's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatric care — a substantially broader footprint than a pure-play cardiac imaging company, but one that frames the institutional investor appetite for AI medical platforms more generally. RadNet, Inc. (NASDAQ: RDNT) has built one of the larger imaging-services-plus-AI businesses through its DeepHealth subsidiary. RadNet's recent acquisition of Gleamer — whose products are deployed in over 2,000 facilities across 30 countries — uniquely positions DeepHealth to expand its impact across routine imaging and accelerate the delivery of automated diagnostics, with the combined entity projected to generate approximately $30 million in annualized recurring AI revenue in 2026.[1] RadNet's scale on the imaging-services side gives it a different kind of moat than a pure software vendor — but the strategic message about AI moving from pilot to recurring revenue is the same one playing out across the sector.GE HealthCare Technologies Inc. (NASDAQ: GEHC) brings the perspective of one of the world's largest installed bases of cardiac imaging equipment. GE HealthCare has been advancing its own cardiac imaging capabilities through AI-powered reconstruction technologies — including AIR Recon DL and Sonic DL — designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes.[1]The fact that the largest incumbent in the space is investing aggressively in AI-augmented cardiac imaging is, if anything, supportive of the thesis that AI-enhanced echocardiography platforms like Ventripoint's are arriving into a market actively being reorganized around AI-driven clinical workflows. Across all four comparables, the same pattern shows up: hospital systems are demanding economic proof, AI cardiac imaging is shifting from pilot to recurring revenue, and AI-augmented echocardiography is increasingly viewed as the most leverageable cardiac modality given its existing scale, portability, and cost profile.What Comes NextVentripoint's near-term catalysts are reasonably visible. The NMPA review process for VMS+ 4.0 in China is now underway, and the Company has said it will provide further updates as the review process progresses.[4] On the commercial side, the LG Consulting Solutions deployment partnership in Northern California is set up to convert clinical evidence into hospital-level economic justification.[6] On the European side, the AEPC exhibition in Padua delivered direct engagement with the largest concentration of paediatric and congenital cardiologists in Europe — a clinical community uniquely well-suited to longitudinal echocardiography-driven follow-up of complex patients.[5]The Company's stated 2026 priority is accelerating the integration of VMS+ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients.[5]For investors tracking the cardiac AI sector, the Company offers a small-cap exposure to a corner of the AI medtech market where the procurement environment, the regulatory environment, and the clinical evidence base have all moved into alignment within the past six months. Whether that alignment translates into accelerating commercial momentum will be measured one deployment, one NMPA decision, and one congress at a time across the back half of 2026.Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageCONTACT INFORMATION
USA News Group
info @therooster-2873Article Sources
[1] https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767 [2] https://www.marketresearch.com/Business-Research-Company-v4006/Cardiac-AI-Monitoring-Diagnostics-Global-44014609/ [3] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report [4] https://finance.yahoo.com/sectors/healthcare/articles/ventripoints-vms-tm-4-0-120000052.html [5] https://finance.yahoo.com/sectors/healthcare/articles/ventripoint-exhibit-59th-annual-meeting-132316747.html [6] https://www.globenewswire.com/news-release/2026/05/13/3294035/0/en/A-Toronto-AI-Cardiac-Diagnostics-Company-Just-Cleared-Three-of-the-Hardest-Validation-Bars-in-Medtech.html [7] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-reportDISCLAIMER NOTICENothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.htmlSOURCE USA News Group Original: Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
US Market News
2月前
Butterfly Network Reports First Quarter 2026 Financial ResultsApril 30, 2026 6:30 AM
Business Wire
Delivered Revenue Above Consensus and Beat Adjusted EBITDA Guidance
Reaffirmed full year Revenue and Adjusted EBITDA Guidance
Delivered quarterly Revenue of $26.5 million in Q1, representing 25% YoY growth
Delivered 69% Gross Margin up 600 bps and Adjusted EBITDA of ($6.1M) up 32% YoY
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “Butterfly opened the year with another strong quarter, coming in above consensus with 25% revenue growth and continued gross margin improvement. We are executing with discipline while continuing to invest in the vast opportunity ahead.”
DeVivo continued, “Our business is starting to come together around three growth engines. Point-of-care ultrasound is scaling globally. Home & Community Care is extending that capability into the patient environment. And Butterfly Embedded is expanding our technology beyond medical ultrasound into new modalities. These are not separate opportunities. They are all part of the same Butterfly platform, a single system that is beginning to work together and compound over time. We are still early, but the direction is clear, and we are building with focus and discipline to drive long-term growth.”
Recent Operational and Strategic Highlights:
Gestational Age AI Tool: Received FDA clearance and initiated rollout of blind-sweep AI tool for rapid fetal age estimation across U.S. and global health markets.
Butterfly Garden Ecosystem: Added two new partners, bringing the portfolio total to 30, while continuing to progress toward additional commercial-ready applications.
Compass AI™ and Enterprise Momentum: Closed first enterprise deal of the year and drove significant growth in the software pipeline since launching the next generation Compass AI solution.
Global Market Expansion: Advancing entry into new markets across the Americas and Asia, including high-growth regions such as Brazil, with iQ3 expansion in multiple countries.
Home & Community Care: Progressing toward first commercial agreement in the first half of 2026, with initial statewide deployment expected in the third quarter.
Butterfly Embedded™: Signed ninth company to the portfolio as of April 2026 and made meaningful development progress with existing partners.
Apollo Platform Development: Continued advancement of next-generation semiconductor architecture designed to significantly increase data processing and compute performance.
Three Months Ended March 31, 2026 Financial Results
Revenue: Total revenue was $26.5 million, representing growth of 25% from $21.2 million in the first quarter of 2025. U.S. revenue was $21.4 million, up 25% from prior year, primarily driven by revenue from our Butterfly Embedded™ partnerships, including our co-development partnership with Midjourney. International revenue increased 23% year-over-year to $5.2 million, largely resulting from increased probe sales in the current year to our distribution partners. Both our U.S. and international revenue also benefited from favorable shifts in our product sales mix towards our higher-priced iQ3 probes.
Gross margin: Gross profit was $18.3 million versus gross profit of $13.4 million in the prior year period. Gross margin increased to 68.9% compared to 63.0% in the prior year period. This increase was primarily due to the relatively higher margin return on our Butterfly Embedded™ licensing revenue, as compared to our core business offerings, as well as a reduction in software amortization costs for our historic software development investments.
Operating expenses: Operating expenses were $32.2 million, up 1% from $31.8 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.2 million, compared to $24.9 million in the first quarter of 2025, largely reflecting increased headcount in the current year from investments we've made in our internal capabilities throughout the past 12 months to support revenue growth as well as higher professional services costs.
Net loss: Net loss was $12.7 million, compared to $14.0 million in the prior year period.
Adjusted EBITDA: Adjusted EBITDA loss was $6.1 million, compared to $9.1 million in the prior year period.
EPS: EPS was $(0.05), compared to $(0.06) in the prior year period.
Adjusted EPS: Adjusted EPS was $(0.03), compared to $(0.04) in the prior year period.
Cash and cash equivalents: Cash and cash equivalents were $138.0 million as of March 31, 2026.
Guidance
Reaffirmed revenue guidance and adjusted EBITDA guidance for the Fiscal Year 2026:
Revenue of $117 million to $121 million, or approximately 20% to 24% growth
Adjusted EBITDA loss of $21 million to $25 million
Provided revenue guidance and adjusted EBITDA guidance for the 2nd Quarter of 2026:
Revenue of $27 million to $31 million, or approximately 24% growth year-over-year at the midpoint
Adjusted EBITDA loss of $6 million to $8 million
Reconciliation of GAAP to Adjusted
Reconciliations of gross profit and gross margin to adjusted gross profit and adjusted gross margin and of net loss and EPS to adjusted net loss, adjusted EBITDA, and adjusted EPS for the three months ended March 31, 2026, and 2025 are provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”
Conference Call
A conference call and webcast to discuss first quarter 2026 financial performance and operational progress is scheduled for 8:00 am ET on April 30, 2026. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:
United States (Local): +1 646 844 6383
United States (Toll-Free): +1 833 470 1428
Global Dial-In Numbers: https://www.netroadshow.com/events/global-numbers?confId=95124
Access Code: 144243
After the live webcast, the call will be archived on Butterfly’s Investor Relations page. In addition, a telephone replay of the call will be available until May 7, 2026, by dialing:
United States (Local): +1 929 458 6194
United States (Toll-Free): +1 866 813 9403
Access Code: 762967
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
Non-GAAP Financial Measures
In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted net loss, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.
The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted net loss, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.
The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of gross profit and gross margin to adjusted gross profit and adjusted gross margin and of net loss and EPS to adjusted net loss, adjusted EBITDA, and adjusted EPS, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, revenue growth, future performance of our ultrasound business and Embedded opportunities (inclusive of co-development, revenue share/commercialization revenue, chip purchases, and/or chip licensing opportunities through the Embedded program), commercialization and plans to deploy our products and services, including expectations regarding the launches of our Compass AI software, Gestational Age AI Tool, our P5 and Apollo chips and fourth-generation technology, finalizing our first commercial Butterfly Home and Community Care agreement, development of products and services, and the size and potential growth of current or future markets for our products and services. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, as applicable, and any related restrictions and limitations on the use of any authorized product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; the success, cost, and timing of our efforts to out-license our intellectual property to third parties; our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to attract and retain customers; our ability to manage our growth effectively; our ability to protect or enforce our intellectual property rights; our ability to maintain the listing of our Class A common stock on the New York Stock Exchange; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
Three months ended March 31,
2026
2025
Revenue:
Product
$
14,653
$
14,164
Software and other services
11,877
7,061
Total revenue
26,530
21,225
Cost of revenue:
Product
6,355
5,824
Software and other services
1,890
2,021
Total cost of revenue
8,245
7,845
Gross profit
18,285
13,380
Operating expenses:
Research and development
9,538
9,924
Sales and marketing
11,417
11,620
General and administrative
10,818
9,600
Other
385
704
Total operating expenses
32,158
31,848
Loss from operations
(13,873
)
(18,468
)
Interest income
1,186
1,651
Interest expense
(279
)
(347
)
Change in fair value of warrant liabilities
413
826
Other income (expense), net
(124
)
2,378
Loss before provision for income taxes
(12,677
)
(13,960
)
Provision for income taxes
—
7
Net loss and comprehensive loss
$
(12,677
)
$
(13,967
)
Net loss per common share attributable to Class A and B common stockholders, basic and diluted
$
(0.05
)
$
(0.06
)
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted
256,516,256
234,923,536
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
March 31, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
137,954
$
150,489
Accounts receivable, net of allowance for credit losses of $1,180 and $1,389 at March 31, 2026 and December 31, 2025, respectively
25,210
26,744
Inventories
59,304
61,389
Current portion of vendor advances
2,908
2,063
Prepaid expenses and other current assets
14,413
8,418
Total current assets
239,789
249,103
Property and equipment, net
16,113
16,587
Intangible assets, net
7,166
7,516
Non-current portion of vendor advances
4,970
5,008
Operating lease assets
12,233
12,652
Other non-current assets
5,651
5,667
Total assets
$
285,922
$
296,533
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
2,817
$
5,442
Deferred revenue, current
22,659
26,909
Accrued purchase commitments, current
131
131
Warrant liabilities, current
—
413
Accrued expenses and other current liabilities
33,973
32,222
Total current liabilities
59,580
65,117
Deferred revenue, non-current
9,631
9,391
Operating lease liabilities
17,017
17,721
Other non-current liabilities
8,472
8,325
Total liabilities
94,700
100,554
Commitments and contingencies
Stockholders’ equity:
Class A common stock $.0001 par value; 600,000,000 shares authorized at March 31, 2026 and December 31, 2025; 234,777,441 and 227,318,426 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
23
23
Class B common stock $.0001 par value; 27,000,000 shares authorized at March 31, 2026 and December 31, 2025; 26,426,937 shares issued and outstanding at March 31, 2026 and December 31, 2025
3
3
Additional paid-in capital
1,083,067
1,075,147
Accumulated deficit
(891,871
)
(879,194
)
Total stockholders’ equity
191,222
195,979
Total liabilities and stockholders’ equity
$
285,922
$
296,533
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Three months ended March 31,
2026
2025
Cash flows from operating activities:
Net loss
$
(12,677
)
$
(13,967
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization, and impairments
1,811
2,360
Non-cash interest expense
280
346
Write-down of inventories
—
52
Stock-based compensation expense
5,542
6,284
Change in fair value of warrant liabilities
(413
)
(826
)
Other
137
56
Changes in operating assets and liabilities:
Accounts receivable
1,409
857
Inventories
2,085
1,423
Prepaid expenses and other assets
(5,979
)
(570
)
Vendor advances
(807
)
29
Accounts payable
(2,643
)
(1,970
)
Deferred revenue
(4,010
)
(470
)
Change in operating lease assets and liabilities
(222
)
(201
)
Accrued expenses and other liabilities
1,593
(5,080
)
Net cash used in operating activities
(13,894
)
(11,677
)
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets, including capitalized software
(950
)
(353
)
Net cash used in investing activities
(950
)
(353
)
Cash flows from financing activities:
Proceeds from exercise of stock options
2,309
133
Net proceeds from share offering
—
81,109
Payments to tax authorities for restricted stock units withheld
—
(2,775
)
Net cash provided by financing activities
2,309
78,467
Net increase (decrease) in cash, cash equivalents, and restricted cash
(12,535
)
66,437
Cash, cash equivalents, and restricted cash, beginning of period
154,504
92,790
Cash, cash equivalents, and restricted cash, end of period
$
141,969
$
159,227
BUTTERFLY NETWORK, INC.
ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN
(In thousands)
(Unaudited)
Three months ended March 31,
2026
2025
Revenue
$
26,530
$
21,225
Cost of revenue
8,245
7,845
Gross profit
$
18,285
$
13,380
Gross margin
68.9
%
63.0
%
Add:
Write-downs and write-offs of inventories
—
52
Adjusted gross profit
$
18,285
$
13,432
Adjusted gross margin
68.9
%
63.3
%
Depreciation and amortization
$
790
$
1,402
% of revenue
3.0
%
6.6
%
BUTTERFLY NETWORK, INC.
ADJUSTED EBITDA AND ADJUSTED EPS
(In thousands, except share and per share amounts)
(Unaudited)
Included on the condensed consolidated statements of operations and comprehensive loss as:
Three months ended March 31,
2026
2025
Net loss
Net loss
$
(12,677
)
$
(13,967
)
Stock-based compensation
Cost of revenue, R&D, S&M, and G&A
5,542
6,284
Write-downs and write-offs of inventories
Cost of revenue
—
52
Change in fair value of warrant liabilities
Change in fair value of warrant liabilities
(413
)
(826
)
Other
Other
385
704
Other expense (income), net
Other income (expense), net
124
(2,378
)
Adjusted net loss
(7,039
)
(10,131
)
Interest income
Interest income
(1,186
)
(1,651
)
Interest expense
Interest expense
279
347
Provision for income taxes
Provision for income taxes
—
7
Depreciation and amortization
Cost of revenue, R&D, S&M, and G&A
1,811
2,360
Adjusted EBITDA
$
(6,135
)
$
(9,068
)
EPS
Net loss per common share
$
(0.05
)
$
(0.06
)
Adjusted EPS
$
(0.03
)
$
(0.04
)
Weighted average shares used to compute EPS and adjusted EPS
Weighted-average shares used to compute net loss per share
256,516,256
234,923,536
View source version on businesswire.com: https://www.businesswire.com/news/home/20260430702349/en/
Investors
John Doherty
Chief Financial Officer, Butterfly
investors@butterflynetwork.com
Media
Liz Snyder
Director, PR & Communications, Butterfly
media@butterflynetinc.com
Original: Butterfly Network Reports First Quarter 2026 Financial Results
US Market News
4月前
Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve OutcomesMarch 3, 2026 12:19 PM
PR Newswire (US)
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Tempus AI (NASDAQ: TEM), RadNet (NASDAQ: RDNT), and GE HealthCare (NASDAQ: GEHC) are converting clinical validation into contracted hospital deployments.
Digital diagnostics platforms are projected to reach $7.67 billion by 2035 at an 18.12% CAGR as health systems shift from evaluating clinical capability to requiring department-level financial proof before adoption[3]. Portable ultrasound, valued at $2.79 billion in 2026, is pushing cardiac assessment beyond traditional imaging labs and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) recently signed a commercial agreement with LG Consulting Solutions to support deployment of its VMS+™ system across Northern California. Under the agreement, LG Consulting will provide economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology. The collaboration will focus on demonstrating the economic and clinical value of VMS+™ imaging and workflow integration across healthcare systems in the Sacramento and San Francisco regions.As part of the agreement, LG Consulting Solutions is purchasing a VMS+™ system for deployment as a demonstration platform to support hospital engagement, clinician training, and economic value assessments. The agreement also includes the potential for revenue sharing related to 3D echocardiography processing services."Economic and operational clarity are critical to accelerating the adoption of new medical technologies," said Hugh MacNaught, President and CEO of VentriPoint Diagnostics. "This collaboration will help hospitals clearly evaluate how VMS+™ can improve cardiac care pathways, enhance clinical insight into cardiac function, and support better patient care while delivering measurable value to healthcare systems."Northern California represents an important market for VentriPoint given its concentration of leading cardiac centers and healthcare systems focused on improving cardiovascular outcomes."Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies," said Lori Gallian, Principal of LG Consulting. "Through this collaboration, we will work directly with cardiac programs to develop practical implementation strategies and demonstrate how VMS+™ can deliver both clinical and operational benefits."CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint In other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) recently reported fourth quarter 2025 revenue of $31.5 million, a 41% increase year-over-year, while generating positive operating cash flow for the first time in the company's history. Full-year 2025 revenue reached $97.6 million, up 19% from the prior year. The company also launched Compass, its AI-powered clinical decision support system designed to guide clinicians through point-of-care ultrasound exams." Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives," said Joseph DeVivo, CEO of Butterfly Network. "From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it's all powered by the same proprietary Ultrasound-on-Chip™ technology. One platform and one diversified strategy that puts us in a strong position to execute and win."The company issued 2026 revenue guidance of $117 million to $121 million, representing 20% to 24% growth. Butterfly's handheld ultrasound platform is used across emergency, primary care, and critical care settings, expanding cardiac and vascular assessment beyond traditional imaging labs.Tempus AI (NASDAQ: TEM) recently reported fourth quarter 2025 revenue of $367.2 million, an 83% increase year-over-year. For the full year, Tempus generated $1.2 billion in revenue and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA, projecting its first year of positive adjusted profitability."In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space," said Eric Lefkofsky, Founder and CEO of Tempus. "The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world."The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists and is expanding its data licensing and clinical trial matching capabilities into cardiovascular diagnostics.RadNet (NASDAQ: RDNT) recently acquired Gleamer, a Paris-based pioneer in AI-powered medical imaging, for up to €230 million. The acquisition positions RadNet's DeepHealth subsidiary as the largest radiology-focused clinical AI provider worldwide, combining Gleamer's BoneView and ChestView FDA-cleared algorithms with DeepHealth's existing suite of mammography, lung, and prostate AI solutions."As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, ultrasound and mammography — is becoming essential to sustaining access, efficiency and quality of care," said Dr. Howard Berger, President and CEO of RadNet. "For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics."Gleamer's products are deployed in over 2,000 facilities across 30 countries. The combined entity is projected to generate approximately $30 million in annualized recurring AI revenue in 2026, with commercial deployment spanning bone fracture detection, chest pathology screening, and advanced mammography analytics.GE HealthCare (NASDAQ: GEHC) recently announced the first implementation of its SIGNA Sprint Elite MRI system at Inova Health System. The platform integrates advanced cardiac imaging capabilities with AI-powered reconstruction technologies including AIR Recon DL and Sonic DL, designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes."Achieving FDA clearance of our next-generation SIGNA MRI technology underscores our commitment to expanding access to high-quality imaging and elevating the standard of care for patients everywhere," said Kelly Londy, President and CEO, MR at GE HealthCare. "As MRI demand continues to rise across clinical areas, providers need solutions that deliver greater efficiency without compromising diagnostic precision. With this new SIGNA generation, we're redefining what's possible – aiming to bring smarter, faster, more sustainable and more consistent imaging to more patients, across more settings, with confidence."The SIGNA Sprint Elite features a compact 22-square-meter footprint, allowing installation in outpatient and community settings previously limited to basic imaging. GE HealthCare's broader imaging portfolio serves more than 1 billion patients annually across 160 countries, with its MR division focused on expanding AI-integrated cardiac and neurological imaging platforms.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint CONTACT:USA NEWS GROUPinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-markethttps://www.precedenceresearch.com/echocardiography-markethttps://www.towardshealthcare.com/insights/digital-diagnostics-system-market-sizinghttps://www.towardshealthcare.com/insights/portable-ultrasound-market-sizingLogo: https://mma.prnewswire.com/media/2838876/5833576/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-networks-turn-to-ai-enhanced-cardiac-imaging-to-cut-costs-and-improve-outcomes-302702775.html
Original: Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes
US Market News
4月前
Butterfly Network Reports Fourth Quarter 2025 Financial ResultsFebruary 26, 2026 6:30 AM
Business Wire
Delivered Record Annual and Quarterly Revenue
Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth
Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history
Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.
Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “Our fourth quarter 2025 performance shows that our strategy is taking hold and our vision is becoming tangible. We delivered record quarterly revenue of $31.5 million, growing 41% year over year, and achieved the first quarter of positive operating cash flow in our company’s history. Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives.”
DeVivo continued, “Butterfly is transitioning from a medical device company into a transformative semiconductor-based company building the foundation for programmable, AI-native imaging and sensing. From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it’s all powered by the same proprietary Ultrasound-on-Chip™ technology. One platform and one diversified strategy that puts us in a strong position to execute and win.”
Recent Operational and Strategic Highlights:
Butterfly Embedded™ Brand: centralized semiconductor co-development activities under the Butterfly Embedded brand, positioning Ultrasound-on-Chip™ as a long-term value driver for the company.
Midjourney Partnership: co-development partnership with Midjourney contributed $6.8 million in Q4 revenue, as part of a larger agreement disclosed in a Form 8-K in November 2025, which details up to $74 million in expected payments to Butterfly over a five-year term.
Compass™ AI: next generation enterprise software launch in the fourth quarter supported business with existing accounts and enterprise pipeline growth.
Cloud and Government Authorizations: achieved GovRAMP and TX-RAMP in the U.S., strengthening Butterfly’s ability to serve federal and Department of Defense markets.
Butterfly Garden Program: announced plan to release Butterfly’s proprietary digital 3D beam steering API to third parties, furthering the ability to develop new AI-enabled image acquisition applications.
HomeCare Commercialization: anticipates finalizing its first commercial HomeCare agreement by mid-2026, with revenue contributions forecasted as early as late 2026 and into 2027.
R&D Roadmap Advancement: moved the fifth-generation P5.1 chip into production and advanced Apollo development, expected to significantly increase data rate and compute performance for next-generation AI-enabled imaging and partner applications.
Three Months Ended December 31, 2025 Financial Results
Revenue: Total revenue was $31.5 million, representing growth of 41% from $22.4 million in the fourth quarter of 2024. U.S. revenue was $26.8 million, up 55% from prior year, driven by revenue from our new co-development partnership with Midjourney as well as increased probe sales in the current year. International revenue decreased 6% year-over-year to $4.7 million, largely resulting from increased sales in the prior year to then-new distribution partners.
Gross margin and adjusted gross margin: Gross profit was $21.2 million versus $13.7 million in the prior year period, and adjusted gross profit was $21.3 million versus $13.7 million in the prior year period. Total gross margin, on a GAAP basis, increased to 67.3% from 61.4% in the prior year period, and adjusted gross margin increased to 67.5% from 61.4% in the prior year period. This increase in both GAAP gross margin and adjusted gross margin was primarily due to the relatively higher margin return on our Butterfly Embedded licensing revenue, as compared to our core business offerings, as well as a reduction in software amortization costs for our historic software development investments.
Operating expenses: Operating expenses were $37.9 million, up 22% from $31.0 million in the prior year period. Total operating expenses excluding stock-based compensation and other expenses were $26.2 million, compared to $25.4 million in the fourth quarter of 2024, reflecting some of the investments we made in 2025 in our sales force and client experience function.
Net loss: Net loss was $15.3 million, compared to $18.1 million in the prior year period.
Adjusted EBITDA: Adjusted EBITDA loss was $3.2 million, compared to $9.1 million in the prior year period.
Adjusted EPS: Adjusted EPS was $(0.02), compared to $(0.05) in the prior year period.
Cash and cash equivalents: Cash and cash equivalents were $150.5 million as of December 31, 2025.
Guidance
Revenue Guidance and Adjusted EBITDA guidance for the Fiscal Year 2026:
Revenue of $117 million to $121 million, or approximately 20% to 24% growth
Adjusted EBITDA loss of $21 million to $25 million
Reconciliation of GAAP to Adjusted
Reconciliations of gross margin to adjusted gross margin and of net loss to adjusted EBITDA and adjusted EPS for the three months and year ended December 31, 2025, and 2024 is provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Non-GAAP Financial Measures.”
Conference Call
A conference call and webcast to discuss fourth quarter and full year 2025 financial performance and operational progress is scheduled for 8:00 am ET on February 26, 2026. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly’s Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:
United States (Local): +1 646 844 6383
United States (Toll-Free): +1 833 470 1428
Global Dial-In Numbers: https://www.netroadshow.com/events/global-numbers?confId=91551
Access Code: 965970
After the live webcast, the call will be archived on Butterfly’s Investor Relations page. In addition, a telephone replay of the call will be available until March 5, 2026, by dialing:
United States (Local): +1 929 458 6194
United States (Toll-Free): +1 866 813 9403
Access Code: 270376
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
Non-GAAP Financial Measures
In addition to providing financial measures based on generally accepted accounting principles in the United States of America (“GAAP”), we provide additional financial measures that are not prepared in accordance with GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS. We present non-GAAP financial measures in order to assist readers of our financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures provide an additional tool for investors to use in comparing our financial performance over multiple periods.
The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit or loss, gross margin, net loss, and EPS.
The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of adjusted gross profit to gross profit or loss, adjusted gross margin to gross margin, and adjusted EBITDA and adjusted EPS to net loss, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, revenue growth, future performance of our ultrasound business and Embedded opportunities (inclusive of co-development, revenue share/commercialization revenue, chip purchases, and/or chip licensing opportunities through the Embedded program), commercialization and plans to deploy our products and services, including expectations regarding the launches of our Compass AI software, our P5 and Apollo chips and fourth-generation technology, finalizing our first commercial HomeCare agreement, development of products and services, and the size and potential growth of current or future markets for our products and services. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, as applicable, and any related restrictions and limitations on the use of any authorized product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; the success, cost, and timing of our efforts to out-license our intellectual property to third parties; our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to attract and retain customers; our ability to manage our growth effectively; our ability to protect or enforce our intellectual property rights; our ability to maintain the listing of our Class A common stock on the New York Stock Exchange; and other risks and uncertainties indicated from time to time in our most recent Annual Report on Form 10-K or in subsequent filings that we make with the Securities and Exchange Commission. We caution that the foregoing list of factors is not exclusive. We caution you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. We do not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based.
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(Unaudited)
Three months ended December 31,
Year ended December 31,
2025
2024
2025
2024
Revenue:
Product
$
18,102
$
14,723
$
63,443
$
54,200
Software and other services
13,412
7,628
34,167
27,856
Total revenue
31,514
22,351
97,610
82,056
Cost of revenue:
Product
8,018
6,641
44,065
24,380
Software and other services
2,275
1,976
7,811
8,845
Total cost of revenue
10,293
8,617
51,876
33,225
Gross profit
21,221
13,734
45,734
48,831
Operating expenses:
Research and development
9,320
8,826
36,262
37,800
Sales and marketing
12,417
11,854
45,876
41,567
General and administrative
10,870
9,943
39,235
39,810
Other
5,325
426
10,776
4,065
Total operating expenses
37,932
31,049
132,149
123,242
Loss from operations
(16,711
)
(17,315
)
(86,415
)
(74,411
)
Interest income
1,314
997
5,911
5,020
Interest expense
(390
)
(334
)
(1,490
)
(1,261
)
Change in fair value of warrant liabilities
620
(1,033
)
2,272
(1,859
)
Other income (expense), net
(59
)
(526
)
2,768
(13
)
Loss before provision for income taxes
(15,226
)
(18,211
)
(76,954
)
(72,524
)
Provision (benefit) for income taxes
66
(109
)
110
(32
)
Net loss and comprehensive loss
$
(15,292
)
$
(18,102
)
$
(77,064
)
$
(72,492
)
Net loss per common share attributable to Class A and B common stockholders, basic and diluted
$
(0.06
)
$
(0.08
)
$
(0.31
)
$
(0.34
)
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted
252,841,134
213,389,209
247,124,365
211,682,760
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
150,489
$
88,775
Accounts receivable, net of allowance for credit losses of $1,389 and $2,583 at December 31, 2025 and December 31, 2024, respectively
26,744
20,793
Inventories
61,389
70,789
Current portion of vendor advances
2,063
5,547
Prepaid expenses and other current assets
8,418
6,709
Total current assets
249,103
192,613
Property and equipment, net
16,587
19,518
Intangible assets, net
7,516
8,916
Non-current portion of vendor advances
5,008
15,042
Operating lease assets
12,652
14,233
Other non-current assets
5,667
5,760
Total assets
$
296,533
$
256,082
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
5,442
$
4,250
Deferred revenue, current
26,909
16,139
Accrued purchase commitments, current
131
131
Warrant liabilities, current
413
—
Accrued expenses and other current liabilities
32,222
27,695
Total current liabilities
65,117
48,215
Deferred revenue, non-current
9,391
7,315
Warrant liabilities, non-current
—
2,685
Operating lease liabilities
17,721
20,398
Other non-current liabilities
8,325
8,637
Total liabilities
100,554
87,250
Commitments and contingencies
Stockholders’ equity:
Class A common stock $.0001 par value; 600,000,000 shares authorized at December 31, 2025 and December 31, 2024; 227,318,426 and 188,626,154 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively
23
19
Class B common stock $.0001 par value; 27,000,000 shares authorized at December 31, 2025 and December 31, 2024; 26,426,937 shares issued and outstanding at December 31, 2025 and December 31, 2024
3
3
Additional paid-in capital
1,075,147
970,940
Accumulated deficit
(879,194
)
(802,130
)
Total stockholders’ equity
195,979
168,832
Total liabilities and stockholders’ equity
$
296,533
$
256,082
BUTTERFLY NETWORK, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Year ended December 31,
2025
2024
Cash flows from operating activities:
Net loss
$
(77,064
)
$
(72,492
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization, and impairments
8,081
10,342
Non-cash interest expense
1,490
1,256
Write-down of inventories
7,975
15
Write-down of vendor advances
9,621
—
Stock-based compensation expense
23,435
21,032
Change in fair value of warrant liabilities
(2,272
)
1,859
Other
799
1,102
Changes in operating assets and liabilities:
Accounts receivable
(6,753
)
(8,503
)
Inventories
1,425
2,218
Prepaid expenses and other assets
(1,616
)
1,304
Vendor advances
3,897
(2,498
)
Accounts payable
1,195
(841
)
Deferred revenue
12,846
435
Change in operating lease assets and liabilities
(855
)
(750
)
Accrued expenses and other liabilities
5,096
3,814
Net cash used in operating activities
(12,700
)
(41,707
)
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets, including capitalized software
(3,348
)
(2,694
)
Sales of property and equipment
—
36
Net cash used in investing activities
(3,348
)
(2,658
)
Cash flows from financing activities:
Proceeds from exercise of stock options
816
64
Proceeds from employee stock purchase plan
1,415
495
Net proceeds from share offering
81,006
—
Payments to tax authorities for restricted stock units withheld
(2,784
)
(739
)
Payments on technology license commitment
(2,691
)
(1,315
)
Net cash provided by (used in) financing activities
77,762
(1,495
)
Net increase (decrease) in cash, cash equivalents, and restricted cash
61,714
(45,860
)
Cash, cash equivalents, and restricted cash, beginning of period
92,790
138,650
Cash, cash equivalents, and restricted cash, end of period
$
154,504
$
92,790
Supplementary cash flow disclosures:
Interest paid
$
810
$
190
Non-cash investing and financing activities:
Acquisition of property, equipment, and intangible assets, including capitalized software
$
396
$
470
BUTTERFLY NETWORK, INC.
ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN
(In thousands)
(Unaudited)
Three months ended December 31,
Year ended December 31,
2025
2024
2025
2024
Revenue
$
31,514
$
22,351
$
97,610
$
82,056
Cost of revenue
10,293
8,617
51,876
33,225
Gross profit
$
21,221
$
13,734
$
45,734
$
48,831
Gross margin
67.3
%
61.4
%
46.9
%
59.5
%
Add:
Write-downs and write-offs of inventories and vendor advances
43
—
17,596
97
Adjusted gross profit
$
21,264
$
13,734
$
63,330
$
48,928
Adjusted gross margin
67.5
%
61.4
%
64.9
%
59.6
%
Depreciation and amortization
$
750
$
1,536
$
4,155
$
6,398
% of revenue
2.4
%
6.9
%
4.3
%
7.8
%
BUTTERFLY NETWORK, INC.
ADJUSTED EBITDA AND ADJUSTED EPS
(In thousands, except share and per share amounts)
(Unaudited)
Included on the condensed consolidated statements of operations and comprehensive loss as:
Three months ended December 31,
Year ended December 31,
2025
2024
2025
2024
Net loss
Net loss
$
(15,292
)
$
(18,102
)
$
(77,064
)
$
(72,492
)
Stock-based compensation
Cost of revenue, R&D, S&M, and G&A
6,361
5,238
23,435
21,032
Write-downs and write-offs of inventories and vendor advances
Cost of revenue
43
—
17,596
97
Change in fair value of warrant liabilities
Change in fair value of warrant liabilities
(620
)
1,033
(2,272
)
1,859
Other
Other
5,325
426
10,776
4,065
Other expense (income), net
Other income (expense), net
59
526
(2,768
)
13
Adjusted net loss
(4,124
)
(10,879
)
(30,297
)
(45,426
)
Interest income
Interest income
(1,314
)
(997
)
(5,911
)
(5,020
)
Interest expense
Interest expense
390
334
1,490
1,261
Provision (benefit) for income taxes
Provision (benefit) for income taxes
66
(109
)
110
(32
)
Depreciation and amortization
Cost of revenue, R&D, S&M, and G&A
1,754
2,507
8,081
10,342
Adjusted EBITDA
$
(3,228
)
$
(9,144
)
$
(26,527
)
$
(38,875
)
Adjusted EPS
$
(0.02
)
$
(0.05
)
$
(0.12
)
$
(0.21
)
Weighted average shares used to compute adjusted EPS
252,841,134
213,389,209
247,124,365
211,682,760
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226681361/en/
Investors
John Doherty
Chief Financial Officer, Butterfly
investors@butterflynetwork.com
Media
Liz Snyder
Director, PR & Communications, Butterfly
media@butterflynetinc.com
Original: Butterfly Network Reports Fourth Quarter 2025 Financial Results
US Market News
5月前
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B MarketJanuary 27, 2026 3:14 PM
PR Newswire (Canada)
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. This high-stakes convergence positions VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), RadNet (NASDAQ: RDNT), Nanox Imaging (NASDAQ: NNOX), and OneMedNet (NASDAQ: ONMD) as the essential engineering nodes where software-defined 3D modeling finally solves radiologist shortages.
Leading programs at institutions like the Mayo Clinic are proving that subscription-based imaging is the ultimate "cheat code" for patient care, turning diagnostic accuracy into measurable ROI through Device-as-a-Service frameworks[5]. By using cloud-enabled solutions to manage complex heart risks, these companies are building high-margin, recurring revenue streams that align perfectly with the new world of value-based care. This isn't just a tech upgrade; it's a total reimagining of how the world tracks heart health for life.Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation.The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation."We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets.The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation.Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth.The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointIn other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) announced plans to release its Beam Steering API in first half 2026, marking the first time third-party developers will access digital 3D beam steering capabilities for AI-enabled ultrasound applications. The API leverages the company's proprietary semiconductor chip technology featuring approximately 9,000 elements that enable software-defined beam steering with off-axis tilt up to 20 degrees without mechanical motion."As the first to offer digital beam steering access to developers, Butterfly Network is changing the game for imaging AI, empowering more advanced tools that simplify image acquisition," said Steve Cashman, Chief Business Officer of Butterfly Network. "As our platform evolves, Butterfly partners gain access to more of our core imaging capabilities, allowing them to build richer, more sophisticated applications."The planned SDK access will support advanced imaging workflows across multiple presets including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Butterfly Network continues expanding its Butterfly Garden and Ultrasound-on-Chip co-development programs, with availability and technical details dependent on ongoing development, regulatory considerations, and partner agreements to democratize ultrasound technology across clinical settings.RadNet (NASDAQ: RDNT) has acquired Radiology Regional, a division of LucidHealth serving Southwest Florida, expanding RadNet's footprint to 13 locations across Naples, Cape Coral, Fort Myers, Port Charlotte and Sarasota. The acquisition adds approximately 400 employees and 44 contracted radiologists to RadNet's operations, with the transaction projected to contribute approximately $100 million in revenue during 2026."RadNet is proud to enter a dynamic region of Florida and build on Radiology Regional's well-trusted history," said Steve Forthuber, President and CEO of Eastern Operations for RadNet. "Through our clinical excellence, operations expertise and AI-powered digital health solutions, RadNet intends to bring accessible and affordable leading-edge patient care, population health screening programs and a focus on early detection of disease to the communities of Southwest Florida."The 13 acquired centers provide comprehensive multi-modality imaging including MRI, CT, PET/CT, mammography, ultrasound and X-ray services built over Radiology Regional's half-century history. RadNet plans to deploy its DeepHealth AI-powered innovations across the acquired facilities to increase clinical accuracy, streamline imaging processes and improve patient experience in the rapidly growing Southwest Florida market.Nanox Imaging (NASDAQ: NNOX) has expanded operations across Serbia, Montenegro, and Bosnia and Herzegovina through a strategic collaboration with Adriamed d.o.o. Beograd, a Belgrade-based medical device distributor. The engagement brings the Nanox.ARC multi-source digital tomosynthesis system to healthcare providers throughout the Western Balkans region."We are building momentum in Europe through this strategic collaboration with Adriamed, whose expertise and regional reach will support our commercial expansion in the Western Balkans," said Erez Meltzer, CEO and Acting Chairman of Nanox Imaging. "Our strategy centers on expanding access to cost-effective imaging solutions through established regional partners."Under the agreement, Adriamed becomes Nanox Imaging's exclusive partner for the Nanox.ARC system and related services across the three-country region. The collaboration follows recent distribution agreements in Greece, Romania, Czech Republic and France as Nanox Imaging continues building its European commercial footprint.OneMedNet (NASDAQ: ONMD) has supported FDA 510(k) clearance of mlHealth 360's Scaida BrainCT-ICH, an AI-powered software solution for rapid detection of intracranial hemorrhage from head CT scans. OneMedNet's regulatory-grade Real-World Data spanning longitudinal electronic medical records, diagnostic imaging, and clinical reports played a critical role in supporting model development, validation, and regulatory submission for the software that analyzes head CT images in approximately 5.97 seconds."We are proud to collaborate with our premier partner mlHealth 360 and to support their efforts in advancing patient care through clinically impactful AI," said Aaron Green, CEO and President of OneMedNet. "Seeing OneMedNet's regulatory-grade Real-World Data—enriched with medical imaging and EMR context—contribute directly to an FDA-cleared solution reinforces the value of high-quality data in accelerating meaningful innovation."This milestone validates OneMedNet's position as a leading Real-World Data provider as life science and AI companies increasingly rely on OneMedNet to support FDA submissions. The depth, diversity, and quality of OneMedNet's curated imaging and clinical datasets enabled mlHealth 360 to access fit-for-purpose data while maintaining data integrity and regulatory compliance.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1. https://www.grandviewresearch.com/industry-analysis/medical-imaging-systems-market
2. https://www.bloomberg.com/news/articles/2026-01-23/new-potent-cancer-treatments-are-raising-heart-risks-for-survivors
3. https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report
4. https://www.jacc.org/doi/10.1016/j.jaccao.2025.08.001
5. https://link.springer.com/article/10.1186/s40959-016-0014-2 Logo - https://mma.prnewswire.com/media/2838876/5737507/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-medical-imaging-revolution-software-native-tech-disrupts-45b-market-302671377.html
Original: AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
TrendTrade2016
1週前
INV4
1週前
iHub News
1週前
glenn1919
1週前
madras50
4月前
lambchops
1年前
Monksdream
1年前
メールアドレスで登録
